Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 26.5 kDa. The protein migrates as 35-43 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
FITC-Labeled Human FOLR1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.
Immobilized Folic acid-BSA conjugate at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) with a linear range of 0.078-1.25 μg/mL (QC tested).
2e5 of Anti-FOLR1 CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) and negative control protein respectively, FITC signals was used to evaluate the binding activity (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Pafolacianine Sodium | Pteroyl-L-Tyr-S0456; OTL-38; EC-17; OTL-0038 | Approved | On Target Laboratories Inc | Cytalux | United States | Ovarian Neoplasms | On Target Laboratories Inc | 2021-11-29 | Ovarian Neoplasms; Inflammatory Bowel Diseases; Neoplasms; Arthritis, Rheumatoid; Breast Neoplasms; Pituitary Neoplasms; Peritoneal Neoplasms; Lung Neoplasms; Gastrointestinal Neoplasms | Details |
Mirvetuximab soravtansine | TAK-853; M9346-Asulfo-SPDB-DM4; IMGN-853; M9346A-sSPDB-DM4 | Approved | Immunogen Inc | Elahere | United States | Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial | Immunogen Inc | 2022-11-14 | Ovarian Neoplasms; Solid tumours; Fallopian Tube Diseases; Cystadenoma, Serous; Carcinoma, Ovarian Epithelial; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinosarcoma; Uterine Neoplasms; Peritoneal Diseases | Details |
Folinic Acid | FTHF | Approved | Autism Spectrum Disorder; Anemia; Down Syndrome; Rectal Neoplasms; Diarrhea; Colorectal Neoplasms; Vitamin B 12 Deficiency | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CBP-1008 | CBP-1008 | Phase 3 Clinical | Coherent Biopharma Suzhou Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms | Details |
Arfolitixorin | ISO-901; 6R-MTHF | Phase 3 Clinical | Isofol Medical Ab | Rectal Neoplasms; Colonic Neoplasms; Osteosarcoma; Colorectal Neoplasms | Details |
Luveltamab tazevibulin | STRO-002 | Phase 3 Clinical | Sutro Biopharma Inc | Solid tumours; Ovarian Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung | Details |
Rinatabart Sesutecan | GEN1184; GEN-1184; PRO-1184 | Phase 3 Clinical | ProfoundBio (Suzhou) Co Ltd | Ovarian Neoplasms; Solid tumours; Cystadenocarcinoma, Serous; Triple Negative Breast Neoplasms; Mesothelioma; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Farletuzumab | MORAb-003 | Phase 2 Clinical | Morphotek Inc | Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung; Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
AZD5335 | AZD5335; AZD-5335 | Phase 2 Clinical | Astrazeneca Plc | Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung | Details |
Farletuzumab ecteribulin | MORAb-202 | Phase 2 Clinical | Morphotek Inc, Bristol-Myers Squibb Company, Eisai Co Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BAT-8006 | BAT8006; BAT-8006 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
4S-CAR-FRa | 4S-CAR-FRa | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms | Details |
CBP-1019 | CBP-1019 | Phase 2 Clinical | Coherent Biopharma Suzhou Co Ltd | Solid tumours; Ovarian Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Urogenital Neoplasms; Lung Neoplasms; Gastrointestinal Neoplasms | Details |
Noscapine-folate conjugate | Phase 1 Clinical | Emory University | Hematologic Neoplasms; Inflammation | Details | |
MOv-18 IgE | MOv-18 IgE; MOv18; MOv-18 | Phase 1 Clinical | King'S College London, Cancer Research UK | Ovarian Neoplasms; Neoplasms | Details |
ITIL-306 | ITIL-306 | Phase 1 Clinical | Instil Bio Inc | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung | Details |
IMGN-151 | IMGN-151 | Phase 1 Clinical | Immunogen Inc | Ovarian Neoplasms; Cystadenocarcinoma, Serous; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Details |
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy(Fred Hutchinson Cancer Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Leukemia, Myeloid, Acute | Details | |
LY-4170156 | LY4170156; LY-4170156 | Phase 1 Clinical | Eli Lilly And Company, Loxo Oncology Inc | Ovarian Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
ZW-191 | ZW-191 | Phase 1 Clinical | Zymeworks Inc | Solid tumours; Ovarian Neoplasms; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung | Details |
AMT-151 | AMT-151 | Phase 1 Clinical | Multitude Therapeutics Inc | Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Adenocarcinoma of Lung; Neoplasms; Mesothelioma; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Endometrioid | Details |
UB-TT170 | UB-TT170; UB-TT-170; UB_TT170; UB_TT-170 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
CBP-1018 | CBP-1018 | Phase 1 Clinical | Coherent Biopharma Suzhou Co Ltd | Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms | Details |
This web search service is supported by Google Inc.